Cargando…

Strategies for improving the management of immune-related adverse events

With the advent of immunotherapeutic agents, durable and dramatic responses have been observed in several hard-to-treat malignancies, outlining a roadmap to conquering cancer. Immune checkpoint inhibitors (ICPi) are a class of immunotherapeutic agents that attack the tumor cells by reinvigorating th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naing, Aung, Hajjar, Joud, Gulley, James L, Atkins, Michael B, Ciliberto, Gennaro, Meric-Bernstam, Funda, Hwu, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Position Article and Guidelines
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735083/ https://www.ncbi.nlm.nih.gov/pubmed/33310772 http://dx.doi.org/10.1136/jitc-2020-001754

Ejemplares similares

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
por: Naidoo, Jarushka, et al.
Publicado: (2023)

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
por: Guidon, Amanda C, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
por: Maus, Marcela V, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
por: Brahmer, Julie R, et al.
Publicado: (2021)

Immune-related adverse events associated with immune checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data
por: Reynolds, Kerry L, et al.
Publicado: (2021)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies
por: Atkins, Michael B, et al.
Publicado: (2023)

Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management
por: Naidoo, Jarushka, et al.
Publicado: (2020)

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
por: Atkins, Michael B, et al.
Publicado: (2022)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
por: Puzanov, I., et al.
Publicado: (2017)

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges
por: Rutella, Sergio, et al.
Publicado: (2020)

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges
por: Cesano, Alessandra, et al.
Publicado: (2020)

Targeting the indoleamine 2,3-dioxygenase pathway in cancer
por: Moon, Yong Wha, et al.
Publicado: (2015)

T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
por: Stephen, Bettzy, et al.
Publicado: (2023)

T-cell agonists in cancer immunotherapy
por: Choi, Yeonjoo, et al.
Publicado: (2020)

Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs
por: Zhang, Tian, et al.
Publicado: (2023)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
por: McNeel, Douglas G., et al.
Publicado: (2016)

Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective
por: Quinn, Casey, et al.
Publicado: (2020)

Position statement for the diagnosis and management of anogenital warts
por: O'Mahony, C., et al.
Publicado: (2019)

Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases
por: dos Reis Neto, Edgard Torres, et al.
Publicado: (2020)

Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis
por: Ma, Christopher, et al.
Publicado: (2022)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
por: Kluger, Harriet, et al.
Publicado: (2023)

Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop
por: Clifton, Guy Travis, et al.
Publicado: (2023)

Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies
por: Anderson, Kristin G, et al.
Publicado: (2023)

The promise of Immuno-oncology: implications for defining the value of cancer treatment
por: Kaufman, Howard L., et al.
Publicado: (2019)

Towards personal health care with model-guided medicine: long-term PPPM-related strategies and realisation opportunities within ‘Horizon 2020’
por: Lemke, Heinz U, et al.
Publicado: (2014)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
por: Rizvi, Naiyer, et al.
Publicado: (2023)

Management of granulomatous lobular mastitis: an international multidisciplinary consensus (2021 edition)
por: Yuan, Qian-Qian, et al.
Publicado: (2022)

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
por: Kluger, Harriet M., et al.
Publicado: (2020)

Patient blood management (PBM) in pregnancy and childbirth: literature review and expert opinion
por: Surbek, Daniel, et al.
Publicado: (2019)

The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
por: Maurer, Marcus, et al.
Publicado: (2022)

Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel
por: Spada, Francesca, et al.
Publicado: (2022)

Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force
por: Tavares, Anna Carolina Faria Moreira Gomes, et al.
Publicado: (2022)

CSACI position statement: systemic effect of inhaled corticosteroids on adrenal suppression in the management of pediatric asthma
por: Issa-El-Khoury, Karine, et al.
Publicado: (2015)

Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology
por: Bianchi, Stefano, et al.
Publicado: (2019)

Indian Society of Critical Care Medicine Position Statement for Central Venous Catheterization and Management 2020
por: Javeri, Yash, et al.
Publicado: (2020)

Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology
por: Pontremoli, Roberto, et al.
Publicado: (2020)

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
por: Rini, Brian I., et al.
Publicado: (2019)

Personalized management of differentiated thyroid cancer in real life – practical guidance from a multidisciplinary panel of experts
por: Campennì, Alfredo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jpsv6ns8r4mpn675a37nci1hcp